Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Paricalcitol in Resectable Pancreatic Cancer
NCT02930902Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab and paricalcitol in pancreatic cancer (PC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of toxicities up to 11 weeks and Number of tumor infiltrating lymphocytes. Started Feb 2017; status: completed.
02
Drugs
pembrolizumabparicalcitol
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02930902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930902.